357166-29-1 Usage
Uses
Used in Pharmaceutical Applications:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate is used as an active pharmaceutical ingredient for the treatment of various types of cancer. It exhibits inhibitory activities towards thymidylate synthase and other folate-dependent enzymes, making it a potent antitumor agent.
Used in Analytical Applications:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate is used as a secondary standard in several analytical applications, including pharmaceutical release testing, method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Used in Quality Control:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate is used as a pharmaceutical secondary standard for application in quality control. It provides a convenient and cost-effective alternative to the preparation of in-house working standards for pharmaceutical laboratories and manufacturers.
Used in Cancer Treatment:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate is used as a chemotherapy drug for the treatment of pleural mesothelioma and non-small cell lung cancer. It acts as a multi-targeted antifolate with antitumor activity, inhibiting folate-dependent enzymes involved in both purine and pyrimidine synthesis.
Used in Drug Delivery Systems:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate can be employed in the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be used as carriers for the compound, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
Used in Activation of Metabolic Pathways:
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate indirectly activates the metabolic kinase AMPK, influencing the mTORC1 pathway in human carcinomas. Activation of AMPK is associated with resistance to the compound, and it induces G0/G1-phase cell cycle arrest in esophageal squamous cell carcinoma cells.
Biochem/physiol Actions
Pemetrexed exhibits its activity against several tumors such as colorectal, breast, gastric, pancreatic, and cervical cancer. It acts as a substrate for multidrug resistance protein transporters.
References
1) Shih?et al.?(1997),?LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes; Cancer Res.?57?1116
2) Hanauske?et al. (2001),?Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors; Oncologist?6?363
3) Rothbart?et al. (2010),?Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas; Cancer Res.?70?10299
4) Qin?et al.?(2019),?AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression; Mol. Oncol.?13?1419
5) Li?et al.?(2019),?Pemetrexed exerts anticancer effects by inducing G0/G1-phase cell cycle arrest and activating the NOXA/Mcl-1 axis in human esophageal squamous cell carcinoma cells; Oncol. Lett.?17?1851
Check Digit Verification of cas no
The CAS Registry Mumber 357166-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,7,1,6 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 357166-29:
(8*3)+(7*5)+(6*7)+(5*1)+(4*6)+(3*6)+(2*2)+(1*9)=161
161 % 10 = 1
So 357166-29-1 is a valid CAS Registry Number.
